Market Overview

Revance Adds Iconic Brand Builder Jill Beraud to Board of Directors


- Beraud will also chair newly-formed Brand Strategy Committee -

Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company
developing a new category of high-performance neuromodulators for use in
treating aesthetic and therapeutic conditions, today announced the
appointment of Jill Beraud to the company's Board of Directors. Ms.
Beraud brings more than 25 years' experience building luxury, fashion,
beauty, and consumer brands. Ms. Beraud will also chair a newly-formed
Revance Brand Strategy Committee focused on establishing the company's
innovative neuromodulator, DaxibotulinumtoxinA for Injection (DAXI), in
the minds of consumers.

"We are delighted to welcome Jill Beraud to our Board at this pivotal
time in our company's trajectory. She arrives at an ideal moment as we
establish a rarity among biotech companies – a Brand Strategy Committee
dedicated to understanding and embracing the consumer mindset," said Dan
Browne, President and Chief Executive Officer (CEO) of Revance. "Jill's
board experience with Levi Strauss and track record of launching
high-growth businesses and powerhouse consumer brands at firms such as
Pepsi, Victoria's Secret and Tiffany & Co., will be invaluable as we
approach commercialization. We look forward to working with her to
unlock the true promise of what our long-acting neuromodulator, DAXI,
can deliver."

As chair of the Revance Brand Strategy Committee, Ms. Beraud will shape
the company's consumer strategy as it prepares to meaningfully transform
patient experiences. With the help of the committee, Revance aims to
shift how neuromodulators are perceived, talked about, and ultimately
experienced by consumers as a result of its game-changing science.

Ms. Beraud is currently CEO and Co-Founder of Sh'nnong Beverage Company,
a business creating a line of functional beverages. Prior to that, she
served as CEO of IPPOLITA, a fine jewelry company with distribution in
Bergdorf Goodman, Neiman Marcus, Nordstrom, and other national
retailers. Previously she held the role of Executive Vice President,
Global Retail and e-Commerce, for Tiffany & Co., where she was
responsible for all global retail, operations, e-commerce, digital, and
omni-channel consumer experience. Ms. Beraud has also managed brands
such as Living Proof and Starbucks/Lipton Joint Ventures, and served as
global chief marketing officer at PepsiCo, where she was responsible for
PepsiCo's $60 billion portfolio of food and beverage brands. She also
spent 13 years at Limited Brands as chief marketing officer of
Victoria's Secret, and Executive Vice President of Marketing for its
broader portfolio of specialty brands, including Bath & Body Works,
Henri Bendel, and Limited Stores. Further, she has a long history of
serving on boards of renowned brands, such as Levi Strauss & Co. and
Elizabeth Arden Holdings. Ms. Beraud was named to Fast Company's
"Most Creative People in Business" in 2013.

"Over the years, I have had the opportunity to launch brands that have
broken the mold in terms of quality and experience, said Ms. Beraud.
"Today, consumers want and deserve more from their chosen products and
services. DAXI has the opportunity to change the game in neuromodulation
and I am thrilled to be a part of the team that will help redefine
outcomes in the space."

About Revance Therapeutics, Inc.

Revance Therapeutics is a biotechnology company focused on developing
transformative neuromodulators to address a broad spectrum of aesthetic
and therapeutic conditions. Revance's lead product candidate,
DaxibotulinumtoxinA for Injection (DAXI), utilizes a unique proprietary
peptide excipient technology combined with highly purified botulinum
toxin type A to produce a novel, long-acting neuromodulator. In
aesthetics, Revance successfully completed its Phase 3 program for DAXI
in glabellar (frown) lines and is currently pursuing U.S. regulatory
approval in 2020, while also running two separate Phase 2 studies in
forehead lines and lateral canthal lines (crow's feet). In therapeutics,
DAXI is being studied in three indications, including a Phase 3 trial in
cervical dystonia, a Phase 2 trial in adult upper limb spasticity, and a
Phase 2 trial in plantar fasciitis, with plans to also study migraine.
Beyond DAXI, Revance also has begun development of a biosimilar to
BOTOX®, which would compete in the existing short-acting neuromodulator
marketplace. More information on Revance may be found at

"Revance Therapeutics" and the Revance logo are registered trademarks of
Revance Therapeutics, Inc.
BOTOX® is a registered trademark of
Allergan, Inc.

Forward-Looking Statements

This press release contains forward-looking statements, including
statements related to the process and timing of, and ability to
complete, current and anticipated future clinical development of our
investigational drug product candidates, the initiation, design, timing
and results of our clinical studies statements about our business and
brand strategy, including with respect to consumer perception and
experiences relating to neuromodulators and/or our potential products,
timeline and other goals and market for our anticipated products, plans
and prospects; including our plans and timing, and potential regulatory
approach and product launch, with respect to our product candidates;
statements about potential benefits of our drug product candidates and
our excipient peptide and other technologies.

Forward-looking statements are subject to risks and uncertainties that
could cause actual results to differ materially from our expectations.
These risks and uncertainties include, but are not limited to: the
outcome, cost, and timing of our product development activities and
clinical trials; the uncertain clinical development process, including
the risk that clinical trials may not have an effective design or
generate positive results; our ability to obtain and maintain regulatory
approval of our drug product candidates; our ability to obtain funding
for our operations; our plans to research, develop, and commercialize
our drug product candidates; our ability to achieve market acceptance of
our drug product candidates; unanticipated costs or delays in research,
development, and commercialization efforts; the applicability of
clinical study results to actual outcomes; the size and growth potential
of the markets for our drug product candidates; our ability to
successfully commercialize our drug product candidates and the timing of
commercialization activities; the rate and degree of market acceptance
of our drug product candidates; our ability to develop sales and
marketing capabilities; the accuracy of our estimates regarding
expenses, future revenues, capital requirements and needs for financing;
our ability to continue obtaining and maintaining intellectual property
protection for our drug product candidates; and other risks. Detailed
information regarding factors that may cause actual results to differ
materially from the results expressed or implied by statements in this
press release may be found in Revance's periodic filings with
the Securities and Exchange Commission (the "SEC"), including factors
described in the section entitled "Risk Factors" of our of our annual
report on Form 10-Q filed May 9, 2019. These forward-looking statements
speak only as of the date hereof. Revance disclaims any obligation to
update these forward-looking statements.

View Comments and Join the Discussion!